Literature DB >> 33596349

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.

Jean-Noel Vergnes1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33596349     DOI： 10.1056/NEJMc2036242

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  8 in total

1.  Seroprevalence of neutralizing antibodies against adenovirus type 26 and 35 in healthy populations from Guangdong and Shandong provinces, China.

Authors:  Haisu Yi; Qian Wang; Jiankai Deng; Hengchun Li; Yingkun Zhang; Zhilong Chen; Tianxin Ji; Wenming Liu; Xuehua Zheng; Qinghua Ma; Xinxin Sun; Yudi Zhang; Xuegao Yu; Mengzhang He; Ling Chen; Ying Feng
Journal:  Virol Sin       Date:  2022-06-25       Impact factor: 6.947

Review 2.  Comprehensive narrative review of real-world COVID-19 vaccines: viewpoints and opportunities.

Authors:  Shelan Liu; Min Kang; Na Zhao; Yali Zhuang; Shijian Li; Tie Song
Journal:  Med Rev (Berl)       Date:  2022-05-25

3.  Acute Hepatitis of Unknown Origin (AHUO)-The Puzzle Ahead.

Authors:  Consolato M Sergi
Journal:  Diagnostics (Basel)       Date:  2022-05-12

Review 4.  mRNA Vaccine: How to Meet the Challenge of SARS-CoV-2.

Authors:  Yingqi Jin; Chen Hou; Yonghao Li; Kang Zheng; Chuan Wang
Journal:  Front Immunol       Date:  2022-01-21       Impact factor: 7.561

5.  Analysis of Neurological Adverse Events Reported in VigiBase From COVID-19 Vaccines.

Authors:  Siddhartha Dutta; Rimplejeet Kaur; Jaykaran Charan; Pankaj Bhardwaj; Sneha R Ambwani; Shoban Babu; Jagdish P Goyal; Mainul Haque
Journal:  Cureus       Date:  2022-01-18

6.  Real-world evidence from over one million COVID-19 vaccinations is consistent with reactivation of the varicella-zoster virus.

Authors:  M Hertel; M Heiland; S Nahles; M von Laffert; C Mura; P E Bourne; R Preissner; S Preissner
Journal:  J Eur Acad Dermatol Venereol       Date:  2022-05-13       Impact factor: 9.228

Review 7.  Development and application of ribonucleic acid therapy strategies against COVID-19.

Authors:  Lin Ning; Mujiexin Liu; Yushu Gou; Yue Yang; Bifang He; Jian Huang
Journal:  Int J Biol Sci       Date:  2022-08-01       Impact factor: 10.750

Review 8.  Development of variant-proof severe acute respiratory syndrome coronavirus 2, pan-sarbecovirus, and pan-β-coronavirus vaccines.

Authors:  Jie Zhou; Zezhong Liu; Guangxu Zhang; Wei Xu; Lixiao Xing; Lu Lu; Qian Wang; Shibo Jiang
Journal:  J Med Virol       Date:  2022-09-25       Impact factor: 20.693
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.